An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 16, 2005, Pages 2855-2866

  Scagliotti, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

NSCLC; Pemetrexed; Targeted therapies; Vitamin supplementation

Indexed keywords

ACETYLSALICYLIC ACID; ALIMITA; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ERYTHROPOIETIN; EVEROLIMUS; FLUOROURACIL; FOLIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IBUPROFEN; IRINOTECAN; L 778123; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; RALTITREXED; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INFORMATION RETRIEVAL; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PALLIATIVE THERAPY; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STEADY STATE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

CARCINOMA, NON-SMALL-CELL LUNG; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 29444459009     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.16.2855     Document Type: Article

References (64)

1. SHIBUYA K, MATHERS CD, BOSCHI-PINTO C, LOPEZ AD, MURRAY CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer (2002) 2(1):37.
2. SOCINSKI MA, STINCHCOMBE TE, HAYES DN: The evolving role of pemetrexed (Alimta) in lung cancer. Semin. Oncol. (2005) 32(2 Suppl. 2):S16-S22.
3. SCHILLER JH, HARRINGTON D, BELANI CP et al: Comparison of four chemotherapy regimens for advanced small-cell lung cancer. N. Engl. J. Med. (2002) 346(2):92-98.
4. KELLY K, CROWLEY J, BUNN PA Jr et al.: Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. (2001) 19(13):3210-3218.
5. SCAGLIOTTI G, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. (2002) 20(21):4285-4291.
6. FOSSELLA F, PEREIRA JR, VON PAWEL J et al.: Randomized, multinational, Phase III study of docetaxel plus combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. (2003) 21(16):3016-3024.
7. PFISTER DG, JOHNSON DH, AZZOLI CG et al.: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. (2004) 22(2):330-353.
8. HANNAN N, SHEPHERD FA, FOSSELLA FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22(9):1589-1597.
9. FELIP E, STAHEL RA, PAVLIDIS N; ESMO GUIDELINES TASK FORCE: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann. Oncol. (2005) 16(Suppl. 1)i28-i29.
10. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J. Clin. Oncol. (2003) 21(12):2237-2246.
11. KRIS M NATALE RB, HERBST R et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290(16):2149-2158.
12. HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J. Clin. Oncol. (2004) 22(5):785-794.
13. GIACCONE G, HERBST RS, MANEGOLD C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. (2004) 22(5):777-784.
14. CUFER T, VRDOLJAK E: Results from a Phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(16S):7035 (Abstract).
15. SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353(2):123-132.
16. GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22(14S):7010 (Abstract).
17. HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE-A Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(25):5892-5899.
18. PAO W, MILLER VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. (2005) 23(11):2556-2568.
19. GIACCONE G, LECHEVALIER N, THATCHER N et al.: A Phase II study of erlotinib as first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(16S):7073 (Abstract).
20. LYNCH TJ, BELL D, HABER D et al.: Correlation of molecular markets including mutations with clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients treated with gefitinib, chemotherapy or gefitinib and chemotherapy in IDEAL and INTACT clinical trials. J. Clin. Oncol. (2005) 23(16S):7006 (Abstract).
21. CAMUS P, KUDOH S, EBINA M: Interstitial lung disease associated with drug therapy. Br. J. Cancer (2004) 91(Suppl. 2):S18-S23.
22. CAPPUZZO F, VARELLA-GARCIA M, SHIGEMATSU H et al.: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. (2005) 23(22):5007-5018.
23. TSAO MS, SAKURADA A, CUTZ JC et al.: Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. (2005) 353(2):133-144.
24. GOVINDAN R: Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res. (2004) 10(12 Pt 2):4241s-4244s.
25. LYNCH TJ, ADJEI AA, BUNN PA Jr et al.: Novel agents in the treatment of lung cancer: conference summary statement. Clin. Cancer Res. (2004) 10(12 Pt 2):4199s-4204s.
26. SHIH C, HABECK LL, MENDELSOHN LG, CHEN VJ, SCHULTZ RM: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv. Enzyme Regul. (1998) 38:135-152.
27. ZHAO R, BABANI S, GAO F, LIU L, GOLDMAN ID: The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin. Cancer Res. (2000) 6(9):3687-3695.
28. MENDELSOHN LG, SHIH C, CHEN VJ, HABECK LL, GATES SB, SHACKELFORD KA: Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin. Oncol. (1999) 26(2 Suppl. 6):42-47.
29. TAYLOR EC, KUHNT D, SHIH C et al.: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H -pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem. (1992) 35(23):4450-4454.
30. SCHULTZ RM, PATEL VF, WORZALLA JF, SHIH C: Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anti-Cancer Res. (1999) 19(1A):437-443.
31. SHIH C, CHEN VJ, GOSSETT LS et al.: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. (1997) 57(6):1116-1123.
32. CHEN VJ, BEWLEY JR, ANDIS SL et al.: Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRFCEM cells. Br. J. Cancer (1998) 78(Suppl. 3):27-34.
33. SCAGLIOTTI GV, SHIN DM, KINDLER HL et al.: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21(8):1556-1561.
34. RUSTHOVEN JJ, EISENHAUER E, BUTTS C et al.: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1999) 17(4):1194-1199.
35. JOHN W, PICUS J, BLANKE CD et al.: Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a Phase II study. Cancer (2000) 88(8):1807-1813.
36. MILLER KD, PICUS J, BLANKE C et al.: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann. Oncol. (2000) 11(1):101-103.
37. O'DWYER PJ, NELSON K, THORNTON DE: Overview of Phase II trials of MTA in solid tumors. Semin. Oncol. (1999) 26(2 Suppl. 6):99-104.
38. PIVOT X, RAYMOND E, LAGUERRE B et al.: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer (2001) 85(5):649-655.
39. HANAUSKE AR, CHEN V, PAOLETTI P, NIYIKIZA C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist (2001) 6(4):363-373.
40. SPIELMANN M, MARTIN M, NAMER M, DUBOIS A, UNGER C, DODWELL DJ: Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin. Breast Cancer (2001) 2(1):47-51.
41. VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21(14):2636-2644.
42. NIYIKIZA C, BAKER SD, SEITZ DE et al.: Homocysteine and methylmalonic acid: markets to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. (2002) 1(7):545-552.
43. RINALDI DA: Overview of Phase I trials of multitargeted antifolate (MTA, LY231514). Semin. Oncol. (1999) 26(2 Suppl. 6):82-88.
44. SHARMA A, JOHNSON RD, WOODWORTH JM: Comparative human pharmacokinetics of MTA in three Phase I studies. Proc. Am. Soc. Clin. Oncol. (1998) 17:900 (Abstract).
45. CLARKE SJ, BOYER MJ, MILLWARD M et al.: A Phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer. (2005) 49(3):401-412.
46. RINALDI DA, KUHN JG, BURRIS HA et al.: A Phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. (1999) 44(5):372-380.
47. MITA AC, SWEENEY CJ, BAKER SD et al.: A Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J. Clin. Oncol. (2005) (In press).
48. HAMMOND LA, FORERO L, BEERAM M et al.: Phase I study of pemetrexed (LY231514) with vitamin supplementation in patients with locally advanced or metastatic cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:532 (Abstract).
49. NAKAGAWA K, KUDOH S, MATSUI K et al.: A Phase I study of pemetrexed supplemented with folic acid (FA) and vitamin B12 (VB12) in Japanese patients with solid tumors. Eur. J. Cancer Suppl. (2004) 2(8):148 (Abstract 486).
50. CLARKE SJ, ABRATT R, GOEDHALS L. BOYER MJ, MILLWARD MJ, ACKLAND SP: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann. Oncol. (2002) 13(5):737-741.
51. SMIT EF, MATTSON K, VON PAWEL J, MANEGOLD, CLARKE S, POSTMUS PE: ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann. Oncol. (2003) 14(3):455-460.
52. SHEPHERD FA, PEREIRA JR, VON PAWEL J et al.: A Phase III study of pemetrexed versus docetaxel in patients with advanced non-small-cell lung (NSCLC) who were previously treated with chemotherapy. Lung Cancer (2003) 41(Suppl. 2):S4 (PL-5).
53. HANNA N, PAUL S, DEMARINIS F et al.: Multiple regression analysis of prognostic variables for survival from the Phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC). Lung Cancer (2003) 41(Suppl. 2):S5 (O-5).
54. BUNN PA Jr, ROSELL R, FOSSELLA F et al.: An exploratory analysis of a Phase III study in patients with advanced non-small cell lung cancer (NSCLC): the impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel. Lung Cancer (2005) 49(2):S86 (PD-068).
55. PUJOL J-L, PAUL S, GATZEMEIER U, KAYITALIRE L BERRY D: Risk-benefit of pemetrexed compared with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy: an analysis of toxicity-free survival. Ann. Oncol. (2004) 15(Suppl. 3):iii87 (Abstract 709P).
56. PUJOL J-L, SHAHARYAR S, KORTSIK C et al.: Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized Phase III trial of pemetrexed versus docetaxel: an exploratory analysis. J. Clin. Oncol. (2004) 22(14S):7135 (Abstract).
57. MANEGOLD C, GATZEMEIER U, VON PAWEL J et al.: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann. Oncol. (2000) 11(4):435-440.
58. SHEPHERD FA, DANCEY J, ARNOLD A et al.: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer (2001) 92(3):595-600.
59. SCAGLIOTTI G, KORTSIK C, DARK GG et al.: Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small-cell lung cancer: a multicenter, randomized Phase II trial. Clin. Cancer Res. (2005) 11(2 Pt 1):690-696.
60. KOSHY S, HERBST RS, OBASAJU CK et al.: A Phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22(14S):7074 (Abstract).
61. CLARKE SJ, BOYER MJ, MILLWARD M et al., A Phase I/II of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer (2005) 49(3):401-412.
62. SEIWERT TY, CONNELL PP, MAUER AM et al.: A Phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer. J. Clin. Oncol. (2005) 23(16S):7062 (Abstract).
63. ALLEGRA CJ: Antifolates: the next millennium. Semin. Oncol. (1999) 26(2 Suppl. 6):1-2.
64. SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Group (ECOG) trial-E4599. Proc. Am. Soc. Clin. Oncol. (2005) 24:4 (Abstract).